What Is Psoriasis?

Psoriasis is a chronic, immune-mediated inflammatory disease that primarily affects the skin and joints. It is characterized by well-demarcated erythematous (reddish) plaques, covered by silvery scales, the result of accelerated epidermal proliferation and chronic inflammation.

Psoriasis is currently recognized as a systemic disease, not just cutaneous. It is associated with a higher risk of cardiovascular disease, metabolic syndrome, type 2 diabetes, depression, and psoriatic arthritis. This understanding has radically changed the therapeutic approach.

Psoriasis affects 2-3% of the world population with no sex predilection. It shows two incidence peaks: ages 15-25 (type I, more severe, associated with HLA-Cw6) and ages 50-60 (type II). The psychosocial impact is profound, with depression and suicidal ideation rates significantly higher than in the general population.

TWO INCIDENCE PEAKS
  1. Type I
    ages 15-25
    More severe, associated with HLA-Cw6.
  2. Type II
    ages 50-60
1

Immune-Mediated Disease

T lymphocytes and the IL23/IL17 axis drive the disease. Psoriasis is neither allergic nor contagious.

2

Systemic Disease

Increased cardiovascular risk, metabolic syndrome, psoriatic arthritis in 30% of patients, and significant psychological impact.

3

Epidermal Proliferation

Skin renewal drops from 28 to 3-5 days, causing buildup of immature keratinocytes — the characteristic scales.

Pathophysiology

Psoriasis is driven by the IL-23/IL-17 axis. Activated dendritic cells produce IL-23, which stimulates Th17 lymphocytes to secrete IL-17A, IL-17F, and IL-22. IL-17 induces production of chemokines, antimicrobial peptides, and pro-inflammatory cytokines in keratinocytes, creating a feedback loop.

IL-22 stimulates keratinocyte hyperproliferation and inhibits their terminal differentiation. The result is epidermal thickening (acanthosis) and parakeratosis (nucleated keratinocytes at the surface) that form the scales. TNF-alpha amplifies inflammation and promotes angiogenesis — the dilated and tortuous vessels of the papillary dermis cause the erythema.

Genetic predisposition is strong: 70% concordance in identical twins. The main susceptibility gene is HLA-Cw6 (chromosome 6p), associated with early-onset type I. Environmental factors such as streptococcal infections, stress, smoking, alcohol, and medications (lithium, beta-blockers) can trigger or exacerbate the disease.

Pathogenic axis of psoriasis: environmental trigger activates dendritic cells, which release IL-23, driving Th17 cells to produce IL-17/IL-22, which act on keratinocytes: hyperproliferation, chemokines, and antimicrobial peptides recruit neutrophils and amplify inflammation
Pathogenic axis of psoriasis: environmental trigger activates dendritic cells, which release IL-23, driving Th17 cells to produce IL-17/IL-22, which act on keratinocytes: hyperproliferation, chemokines, and antimicrobial peptides recruit neutrophils and amplify inflammation
2-3%
of the world population affected
30%
develop psoriatic arthritis
3-5 days
skin renewal cycle (vs. 28 days normal)
70%
concordance in identical twins

Symptoms

The most common form is plaque psoriasis (vulgaris), representing 80-90% of cases. The plaques are well demarcated, erythematous, with adherent silvery scales. They are preferentially located on the scalp, elbows, knees, lower back, and nails.

Manifestations of Psoriasis

  • Erythematosquamous plaques

    Reddish, well-demarcated plaques covered by silvery scales. When the scales are removed, pinpoint bleeding appears (Auspitz sign).

  • Pruritus and discomfort

    Itching affects 60-90% of patients and ranges from mild to intense. Pain and burning occur in plaque fissures.

  • Nail involvement

    Pinpoint depressions (pitting), onycholysis (detachment), subungual hyperkeratosis, "oil-drop" spots. Present in 50% of patients with cutaneous psoriasis.

  • Scalp involvement

    Thick, heavily scaling plaques that may extend beyond the hairline. Affects 50-80% of patients.

  • Psoriatic arthritis

    Joint pain, swelling, and stiffness. May affect peripheral joints and/or spine (spondylitis). Active screening is recommended.

  • Koebner phenomenon

    Lesions appear in áreas of skin trauma (scars, abrasions, sunburns). Important for patient counseling.

Clinical Forms of Psoriasis

FormFeaturesFrequency
Plaque (vulgaris)Chronic erythematosquamous plaques on extensors, scalp, lower back80-90%
GuttateSmall scattered papules, often following streptococcal infection2-10%
InverseSmooth erythema without scales in folds (axillary, inguinal, submammary)3-7%
PustularSterile pustules on an erythematous base; may be localized (palmoplantar) or generalized1-3%
ErythrodermicGeneralized erythema (>90% of body surface). Dermatologic emergency<1%

Diagnosis

The diagnosis is clinical in the great majority of cases. Skin biopsy is reserved for atypical presentations. Evaluation should include determination of severity (PASI, BSA, DLQI), screening for psoriatic arthritis, and assessment of metabolic and cardiovascular comorbidities.

The PASI (Psoriasis Área and Severity Index) assesses the extent and severity of plaques in four body regions. The DLQI (Dermatology Life Quality Index) measures the impact on quality of life. The combination of PASI ≥10 or BSA ≥10 or DLQI ≥10 defines moderate-to-severe disease, with indication for systemic therapy.

Differential Diagnosis

Psoriasis is recognized by its erythematous plaques with silvery scale, but can be confused with other inflammatory dermatoses — especially in atypical forms or at special sites such as the scalp and nails.

Differential Diagnosis

Eczema

Read more
  • Poorly defined lesions
  • Vesicles
  • Intense pruritus
Diagnostic testsBiopsy

Seborrheic Dermatitis

  • Scalp and face
  • Yellowish greasy scale
  • No thick plaques

Lichen Planus

  • Violaceous papules
  • Wickham striae
  • Oral mucosa
Diagnostic testsBiopsy

Guttate Psoriasis

  • Drop-shaped lesions after streptococcal infection
  • Young patients
  • Sudden onset

Rosacea

Read more
  • Central face
  • Erythema without plaques
  • No silvery scale

Lichen Planus: When Biopsy Decides

Lichen planus is a T-lymphocyte-mediated inflammatory disease affecting skin, mucosa, and nails. Polygonal violaceous papules with surface white reticulated striae (Wickham striae) and oral mucosal involvement (white reticular pattern) are highly characteristic. However, hypertrophic lichen planus on the lower limbs may mimic psoriasis with thick plaques.

Histologic biopsy is definitive: the band-like lymphocytic infiltrate at the dermoepidermal junction with basal-layer (vacuolar) degeneration is the lichen planus pattern, distinct from the acanthosis with parakeratosis and Munro microabscesses of psoriasis. Treatment of lichen planus — especially the erosive oral form — requires potent topical or systemic corticosteroids.

Seborrheic Dermatitis vs. Scalp Psoriasis

Distinguishing seborrheic dermatitis from scalp psoriasis is one of the most frequent diagnostic challenges in dermatology. In seborrheic dermatitis, the scale is yellowish and greasy, with diffuse erythema and no well-demarcated borders; the scalp is the preferred site, along with eyebrows, nostrils, and nasolabial folds. In psoriasis, plaques have sharp borders, silvery scale, and often extend beyond the hairline.

"Sebopsoriasis" — overlap of seborrheic dermatitis and psoriasis — is a recognized entity, especially in individuals with genetic predisposition for psoriasis. Treatment of sebopsoriasis combines antifungals (for the Malassezia component) with topical corticosteroids and, eventually, vitamin D analogues.

Seborrheic dermatitis

  • The scale is yellowish and greasy
  • The erythema is diffuse, with no well-demarcated borders
  • The scalp is the preferred site, along with eyebrows, nostrils, and nasolabial folds

Scalp psoriasis

  • The scale is silvery
  • Plaques have sharp borders
  • Plaques often extend beyond the hairline

Guttate Psoriasis: Infectious Trigger and Course

Guttate psoriasis is triggered by streptococcal throat infections (pharyngotonsillitis) in genetically susceptible individuals, typically children and young adults. It presents with acute eruption of multiple erythematosquamous papules and small plaques ("droplike") on the trunk and extremities, 2 to 3 weeks after infection. It is often the initial presenting form of psoriasis.

In most cases, guttate psoriasis resolves spontaneously in 2 to 3 months. Treatment of an active streptococcal infection is indicated, but a benefit of antibiotics on the course of guttate psoriasis has not been demonstrated. Some patients progress to chronic plaque psoriasis. UVB phototherapy is highly effective in persistent cases.

Treatment

Treatment is tiered according to severity. Topical therapies for mild forms, phototherapy for moderate forms, and systemic therapies (biologics and small molecules) for moderate-to-severe forms. The anti-IL-17 and anti-IL-23 biologics represent the greatest advance, with unprecedented PASI 90-100 rates.

First line
Mild: Topical Therapy

Topical corticosteroids (foundation of topical treatment), vitamin D analogues (calcipotriene), corticosteroid + calcipotriene combination (more effective). Calcineurin inhibitors for face and folds. Emollients always.

Narrowband UVB, 2-3x/week
Moderate: Phototherapy

Narrowband UVB phototherapy: induces apoptosis of pathogenic T lymphocytes and immunomodulation. Effective in 60-70% of patients. PUVA (psoralen + UVA) is an alternative for thick plaques.

When phototherapy is inadequate
Moderate to Severe: Conventional Systemics

Methotrexate: standard for decades, also effective in psoriatic arthritis. Cyclosporine: rapid action, use limited to 1-2 years. Acitretin: for pustular and palmoplantar psoriasis.

Targeted treatment
Moderate to Severe: Biologics

Anti-TNF (adalimumab, infliximab). Anti-IL-17 (secukinumab, ixekizumab): PASI 90 in 60-70%. Anti-IL-23 (guselkumab, risankizumab): PASI 90 in 70-85%, convenient dosing. JAK/TYK2 inhibitors (deucravacitinib): oral.

Do

  • Always use emollients
  • Identify and avoid the individual triggers of flares
  • Keep sun exposure gradual and controlled, never excessive

Avoid

  • Excessive sun exposure: sunburn can trigger the Koebner effect (worsening lesions)
  • Alcohol: it aggravates psoriasis and interferes with hepatotoxic drugs such as methotrexate
The essentials so far
  1. Treatment is tiered according to severity.
  2. Topical therapies for mild forms, phototherapy for moderate forms, and systemic therapies for moderate-to-severe forms.
  3. The anti-IL-17 and anti-IL-23 biologics represent the greatest advance, with unprecedented PASI 90-100 rates.
Continue: acupuncture as treatment

Acupuncture as Treatment

Acupuncture has been studied in psoriasis with a focus on its immunomodulatory effects, particularly modulation of the Th17 response and reduction of pro-inflammatory cytokines such as TNF-alpha and IL-17. Experimental studies demonstrate that acupuncture may reduce keratinocyte proliferation and dermal angiogenesis in animal models.

Hypothesized mechanisms — still without robust clinical validation in human psoriasis — include possible modulation of the hypothalamic-pituitary-adrenal axis, reduced cutaneous oxidative stress, effects on local microcirculation, and neuroendocrine modulation of stress (a recognized trigger of flares).

In clinical practice, acupuncture is a complementary therapy with potential benefit for pruritus control, stress reduction, and quality-of-life improvement. It does not replace conventional dermatologic or biologic therapies in moderate-to-severe forms.

Prognosis

Psoriasis is a chronic, incurable disease, but control is excellent in the biologics era. Mild forms respond well to topical therapies. Moderate-to-severe forms, previously hard to control, can now achieve clear or nearly clear skin with biologics.

The main long-term risk is cardiovascular. Patients with severe psoriasis have increased cardiovascular risk, with a higher risk of myocardial infarction and shorter life expectancy described in population studies. Adequate control of systemic inflammation with biologics may reduce this cardiovascular risk while also improving the skin.

Myths and Facts

Myth vs. Fact

Myth

Psoriasis is contagious.

Fact

Psoriasis is not contagious in any way. It is an autoimmune/immune-mediated disease with a genetic basis and cannot be transmitted by touch, kissing, sexual intercourse, or any other form of contact.

Myth vs. Fact

Myth

Psoriasis is just a skin disease.

Fact

Psoriasis is a systemic inflammatory disease. Beyond the skin, it can affect joints (psoriatic arthritis in 30%) and is linked to higher cardiovascular risk, type 2 diabetes, depression, and metabolic syndrome.

Myth vs. Fact

Myth

Sun always improves psoriasis.

Fact

Moderate sun exposure may improve lesions through UVB, but sunburn can trigger the Koebner effect (worsening lesions). Exposure should be gradual and controlled, never excessive.

When to Seek Help

Frequently Asked Questions

Frequently Asked Questions